Biogen Hemophilia Spin Out Bioverativ On Track For Early 2017
Bioverativ was unveiled as the name for Biogen’s spin out; an initial Form 10 registration will be filed with SEC later this week.
You may also be interested in...
Fourth-quarter earnings reports from J&J, Novartis, AbbVie and Biogen all missed on sales but more worryingly, lower sales from some recent acquisitions contributed to the missed expectations. The time from child star to problem child seems to be shorter than I remember.
Bioverativ will spin out from Biogen Feb. 1 as a biotech focused on rare blood disorders, particularly hemophilia. With two marketed drugs, a lifecycle management strategy and leverage to bring in new assets, CEO John Cox says the company is ready to go it alone.
Sobi's outgoing US-based CEO says his extended handover will “maintain continuity” as Sweden's rare disease specialist searches for a successor who will "stay closer to home" as it conducts key product launches.